University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy : Results of the Randomized FOCUS4-N Trial

Simple item page
dc.contributor.authorAdams, Richard A.
dc.contributor.authorFisher, David J.
dc.contributor.authorGraham, Janet
dc.contributor.authorSeligmann, Jenny F.
dc.contributor.authorSeymour, Matthew
dc.contributor.authorKaplan, Richard
dc.contributor.authorYates, Emma
dc.contributor.authorParmar, Mahesh
dc.contributor.authorRichman, Susan D.
dc.contributor.authorQuirke, Philip
dc.contributor.authorButler, Rachel
dc.contributor.authorBrown, Ewan
dc.contributor.authorCollinson, Fiona
dc.contributor.authorFalk, Stephen
dc.contributor.authorWasan, Harpreet
dc.contributor.authorShiu, Kai-Keen
dc.contributor.authorMiddleton, Gary
dc.contributor.authorSamuel, Leslie
dc.contributor.authorWilson, Richard H.
dc.contributor.authorBrown, Louise C.
dc.contributor.authorMaughan, Timothy S.
dc.contributor.authorFOCUS Trial Collaboration
dc.contributor.institutionUniversity of Aberdeen.Medicine, Medical Sciences & Nutritionen
dc.contributor.institutionUniversity of Aberdeen.Aberdeen Centre for Evaluationen
dc.date.accessioned2021-11-24T09:43:01Z
dc.date.available2021-11-24T09:43:01Z
dc.date.issued2021-11-20
dc.descriptionSUPPORT Supported by Cancer Research UK and the National Institute for Health Research (NIHR).en
dc.description.statusPeer revieweden
dc.format.extent42
dc.format.extent1052347
dc.identifier200470280
dc.identifierda21a725-c787-4fe5-9564-1a5a30dccfa4
dc.identifier34516759
dc.identifier85121990810
dc.identifier.citationAdams, R A, Fisher, D J, Graham, J, Seligmann, J F, Seymour, M, Kaplan, R, Yates, E, Parmar, M, Richman, S D, Quirke, P, Butler, R, Brown, E, Collinson, F, Falk, S, Wasan, H, Shiu, K-K, Middleton, G, Samuel, L, Wilson, R H, Brown, L C, Maughan, T S & FOCUS Trial Collaboration 2021, 'Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy : Results of the Randomized FOCUS4-N Trial', Journal of Clinical Oncology, vol. 39, no. 33, JCO.21.01436, pp. 3693-3704. https://doi.org/10.1200/JCO.21.01436en
dc.identifier.doi10.1200/JCO.21.01436
dc.identifier.iss33en
dc.identifier.issn0732-183X
dc.identifier.otherRIS: urn:DD8C999877AC6619E48FC8DE1CC26E8B
dc.identifier.otherORCID: /0000-0002-8402-8670/work/100345920
dc.identifier.urihttps://hdl.handle.net/2164/17553
dc.identifier.vol39en
dc.language.isoeng
dc.relation.ispartofJournal of Clinical Oncologyen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectR Medicineen
dc.subjectCancer Research UKen
dc.subjectNational Institute for Health Research (NIHR)en
dc.subject.lccRen
dc.titleCapecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy : Results of the Randomized FOCUS4-N Trialen
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Adams_etal_JCO_Capecitabine_Versus_Active_VoR.pdf
Size:
1 MB
Format:
Adobe Portable Document Format
Download

Collections

All research